ArticleFrontiers in immunology2026
Mesenchymal stem cell-derived extracellular vesicles ameliorate heat stroke-induced hippocampal injury and modulate VIM-AS1-associated miR-34a-5p/Per2 signaling.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Central nervous system (CNS) injury is a major determinant of mortality and persistent disability after heat stroke. Mesenchymal stromal/stem cell-derived extracellular vesicles (MSC-EVs) are candidate cell-free immunomodulatory therapeutics, but their effects and molecular correlates in heat stroke-associated brain injury remain incompletely defined. We investigated whether MSC-EVs attenuate hippocampal inflammation and alter microglial phenotype-associated markers after heat stroke. Methods: Human umbilical cord MSC-EVs were isolated by differential ultracentrifugation and characterized by transmission electron microscopy, nanoparticle tracking analysis, and immunoblotting for EV-enriched and non-EV markers. In a mouse heat stroke model, MSC-EVs (200 μg total protein per mouse) were administered intravenously. Neurological outcomes, hippocampal pathology, inflammatory mediators, IBA1 immunoreactivity, and phenotype-associated markers were evaluated. BV2 heat-stress and MSC co-culture experiments were used to examine VIM-AS1-associated miR-34a-5p/Per2 signaling. Results: MSC-EV treatment improved survival and neurological scores and reduced hippocampal injury and inflammatory readouts after heat stroke. In mouse brain and BV2 models, treatment was associated with lower expression of inflammatory-associated markers and higher expression of repair-associated markers. EV RNA sequencing identified abundant VIM-AS1. VIM-AS1 gain- and loss-of-function experiments altered miR-34a-5p and Per2 expression, while miR-34a-5p directly repressed a conserved mouse Per2 3'UTR reporter. VIM-AS1 overexpression also improved inflammatory and neurological readouts Conclusions: MSC-EVs attenuated heat stroke-induced hippocampal injury and were associated with coordinated changes in VIM-AS1, miR-34a-5p, and Per2. These findings support MSC-EVs and VIM-AS1-associated signaling as candidates for further mechanistic investigation, while not establishing VIM-AS1 as the sole or dominant active EV cargo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.